21209058|t|Folding stability of amyloid-beta 40 monomer is an important determinant of the nucleation kinetics in fibrillization.
21209058|a|Amyloid formation is initiated by protein misfolding, followed by self-association to ultimately form amyloid fibrils. The discovery of toxic prefibrillar oligomers in many amyloidosis underscores the importance of understanding the folding mechanism prior to such aggregation. Here, we investigated the folding properties of the natively unfolded amyloid-beta (Abeta) peptide and the familial variants (A21G, E22Q, E22G, E22K, and D23N) in Alzheimer's disease (AD). In combinations of native electrophoresis, analytical ultracentrifugation, fluorescence emission, and far-UV circular dichroism, we showed that all Abeta40 variants are predominantly monomeric with similar residual secondary structures, but distinct hydrophobic-exposed protein surfaces. Guanidine hydrochloride (GdnHCl) denaturation in the absence and presence of trifluoroethanol (TFE) showed that Abeta variants adopt an apparent 2-state equilibrium model with different stabilities, in which wild type is less stable than A21G but more stable than D23N and E22 mutants. By correlating the folding stability with the nucleation phase in fibrillization, we found the more stable the variant, the slower the nucleation, except for D23N. Besides, the unfolding of Abeta conformation leads to reduced formation of mature fibrils, but an increase in nonfibrillar, amorphous type of aggregates. Overall, we demonstrated that folding stability of Abeta is an important determinant of the nucleation kinetics.
21209058	119	126	Amyloid	Disease	MESH:C000718787
21209058	221	228	amyloid	Disease	MESH:C000718787
21209058	292	303	amyloidosis	Disease	MESH:D000686
21209058	467	479	amyloid-beta	Gene	351
21209058	481	486	Abeta	Gene	351
21209058	523	527	A21G	ProteinMutation	tmVar:p|SUB|A|21|G;HGVS:p.A21G;VariantGroup:2;CorrespondingGene:351;RS#:763852444;CorrespondingSpecies:9606;CA#:9987752
21209058	529	533	E22Q	ProteinMutation	tmVar:p|SUB|E|22|Q;HGVS:p.E22Q;VariantGroup:0;CorrespondingGene:351;CorrespondingSpecies:9606
21209058	535	539	E22G	ProteinMutation	tmVar:p|SUB|E|22|G;HGVS:p.E22G;VariantGroup:0;CorrespondingGene:351;CorrespondingSpecies:9606
21209058	541	545	E22K	ProteinMutation	tmVar:p|SUB|E|22|K;HGVS:p.E22K;VariantGroup:0;CorrespondingGene:351;CorrespondingSpecies:9606
21209058	551	555	D23N	ProteinMutation	tmVar:p|SUB|D|23|N;HGVS:p.D23N;VariantGroup:1;CorrespondingGene:351;RS#:1297968881;CorrespondingSpecies:9606
21209058	560	579	Alzheimer's disease	Disease	MESH:D000544
21209058	581	583	AD	Disease	MESH:D000544
21209058	874	897	Guanidine hydrochloride	Chemical	MESH:D019791
21209058	899	905	GdnHCl	Chemical	MESH:D019791
21209058	951	967	trifluoroethanol	Chemical	MESH:D014270
21209058	969	972	TFE	Chemical	MESH:D014270
21209058	986	991	Abeta	Gene	351
21209058	1147	1150	E22	ProteinMutation	tmVar:p|Allele|E|22;VariantGroup:0;CorrespondingGene:351;CorrespondingSpecies:9606
21209058	1318	1322	D23N	ProteinMutation	tmVar:p|SUB|D|23|N;HGVS:p.D23N;VariantGroup:1;CorrespondingGene:351;RS#:1297968881;CorrespondingSpecies:9606
21209058	1350	1355	Abeta	Gene	351
21209058	1529	1534	Abeta	Gene	351
21209058	Association	MESH:D000544	RS#:763852444;HGVS:p.A21G;CorrespondingGene:351
21209058	Association	MESH:D000544	RS#:1297968881;HGVS:p.D23N;CorrespondingGene:351
21209058	Association	MESH:D000544	HGVS:p.E22K;CorrespondingGene:351
21209058	Association	MESH:D000544	HGVS:p.E22G;CorrespondingGene:351
21209058	Association	MESH:D000544	351
21209058	Association	MESH:D000544	HGVS:p.E22Q;CorrespondingGene:351
21209058	Association	MESH:D000544	351

